Amyloid beta (Abeta) Kits ELISA

Abeta encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. De plus, nous expédions beta Amyloid Anticorps (181) et beta Amyloid Protéines (3) et beaucoup plus de produits pour cette protéine.

list all ELISA KIts Gène GeneID UniProt
Abeta 351 P05067
Anti-Rat Abeta Abeta 54226 P08592
Anti-Souris Abeta Abeta 11820 P12023
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top beta Amyloid Kits ELISA sur anticorps-enligne.fr

Showing 1 out of 1 products:

Catalogue No. Reactivité Sensibilité Gamme Images Quantité Livraison Prix Détails
Humain 10 pg/mL 312-20000 pg/mL Representative Standard Curve 96 Tests 15 to 16 Days
$550.00
Détails

Plus Kits ELISA pour beta Amyloid partenaires d'interaction

Human Amyloid beta (Abeta) interaction partners

  1. This study showed that 24-month-old AppNL/NL mice, despite presenting an age dependent increase in insoluble amyloid-beta oligomers in the prefrontal cortex, they do not develop amyloid plaque deposition, reactive gliosis, or cognitive deficits.

  2. This study demonstrated that Progress of Brain Amyloid Deposition in Familial Alzheimer's Disease with Taiwan D678H APP Mutation.

  3. these data reveal an important role for APP in the amyloidogenic aspects of AD but challenge the idea that increased APP levels are solely responsible for increasing specific phosphorylated forms of tau or enhanced neuronal cell death in Down syndrome-associated AD pathogenesis.

  4. This study explores the mechanism of ABETA (1-40) fiber elongation. A Markov state model shows that the unfolded monomer is trapped at the end of the fiber in a set of interconverting antiparallel beta hairpin conformations.

  5. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-beta oligomers.

  6. These findings suggest a role for TREM2 in the brain of HIV+ individuals may deserve more investigation as a biomarker for HIV-associated neurocognitive disorders and as a possible therapeutic

  7. Overall these data suggest that the assembly of mixtures of Abeta peptides into different Abeta seeds leads to the formation of distinct subtypes of amyloid having distinctive physicochemical and biological properties which result in the generation of distinct Alzheimer's disease molecular subgroups.

  8. These results suggest a role of cPLA2 activation in facilitating oligomeric Abeta endocytosis by microglial cells through regulation of the membrane-cytoskeleton connectivity.

  9. APP-deficient cells exhibited elevated resting calcium levels in the ER and prolonged emptying of ER calcium stores upon the cyclopiazonic acid-induced inhibition of sarco-endoplasmic reticulum calcium-ATPase. These effects could be ascribed to lower ER calcium leakage rates. Translocation of the endogenous ER calcium sensor STIM1 to its target channel Orai1 was delayed following ER calcium store depletion.

  10. Super-resolution transient amyloid binding microscopy was used to image amyloid fibrils from multiple polypeptides, oligomeric, and fibrillar structures formed during different stages of amyloid-beta aggregation.

  11. This study data demonstrate that low expression of APP is sufficient to drive histopathological and cognitive changes in mice without overexpression or excessive plaque deposition.

  12. This article reviews the current applications of Mass Spectrometry (MS) in the search for possible ABETA biomarkers of Alzheimer's disease to help the diagnosis of the disease. Recent examples of the important contributions that MS has given to prove or build theories on the molecular pathways involved with such terrible disease are also reviewed. [review]

  13. These findings indicate that under physiological conditions, expression of APP in cerebral vascular endothelium plays an important protective function by maintaining constitutive expression of eNOS .

  14. Abeta oligomers bind herpesvirus surface glycoproteins, accelerating beta-amyloid deposition and leading to protective viral entrapment activity in 5XFAD mouse and 3D human neural cell culture infection models against neurotropic herpes simplex virus 1 (HSV1) and human herpesvirus 6A and B.

  15. the inhibition of APPswe-induced secretion of inflammatory cytokines and the suppression of NF-kappaB activation by miR-15b were validated...Our study suggests that miR-15b inhibits Abeta accumulation through targetting NF-kappaB signaling and BACE1 and serves as a potential molecular target for Alzheimer's disease (AD) therapy

  16. This case study reports the first detailed clinical description of Val717Phe mutation, demonstrating amnestic AD phenotype with seizures, myoclonus, and Parkinsonism, and yields an overview of related autosomal dominantly inherited exonic mutations in the APP gene.

  17. CSF Abeta levels and white matter lesion loads (WM-LL) suggests a direct link between amyloid pathology and WM macrostructural and microstructural damage in Alzheimer's disease. There was increased WM-LL in Abeta(+) compared with both, healthy controls and Abeta(-) Alzheimer's patients.

  18. The findings reveal a novel mechanism whereby GSK3beta stimulates amyloidogenic processing of APP by phosphorylation of FE65 at threonine 579.

  19. A Toxic Conformer of Abeta42 with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease.

  20. Alzheimer's disease-associated TREM2 variants bind Abeta with equivalent affinity but show loss of function in terms of signaling and Abeta internalization.

Mouse (Murine) Amyloid beta (Abeta) interaction partners

  1. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-beta oligomers.

  2. Together these data indicate that ONA induces APP expression and that gamma-secretase cleavage of APP releases AICD, which upregulates JNK3 leading to RGC death. This pathway may be a novel target for neuronal protection in optic neuropathies and other forms of neurotrauma.

  3. In addition to regulating aspects of neuronal metabolism, APP is an important regulator of whole body energy expenditure and glucose homeostasis under high fat feeding conditions.

  4. These findings indicate that under physiological conditions, expression of APP in cerebral vascular endothelium plays an important protective function by maintaining constitutive expression of eNOS .

  5. NRBF2 plays an important role in regulating degradation of APP-C-terminal fragments through modulating autophagy.

  6. These results provide evidence that both central circadian rhythms and local clock function influence Abeta dynamics and plaque formation.

  7. These data identified APP and APLP2 as modulators of normal myelination and demyelination/remyelination conditions.

  8. these findings suggest that endogenous Abeta is involved in memory forgetting in the normal brain.

  9. pterostilbene attenuated the neuroinflammatory response induced by Abeta1-42 in microglia through inhibiting the NLRP3/caspase-1 inflammasome pathway, indicating that pterostilbene might be an effective therapy for AD.

  10. Abeta40 and Abeta42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution.

  11. APP/GBR complex formation links presynaptic GBR trafficking to Abeta formation.

  12. APP knockout increases synaptic GluA1, PSD-95 and synaptophysin expression and reduces drebrin expression.

  13. data indicate that Drp1 is a direct target of Cdk5, and Cdk5-mediated phosphorylation of Drp1 at Serine 579 regulates Abeta1-42 induced mitochondrial fission and neuronal toxicity.

  14. miR98 reduced the production of Abeta and improved oxidative stress and mitochondrial dysfunction through activation of the Notch signaling pathway by binding to HEY2 in Alzheimer's disease mice.

  15. Heme and Hb suppress immune activity of primary mouse astrocytes by reducing expression of several proinflammatory cytokines (e.g. RANTES (regulated on activation normal T cell expressed and secreted)) and the scavenger receptor CD36 and reducing internalization of Abeta(1-42) by astrocytes.

  16. extracellular cholesterol concentration in serum under conditions of Npc1 deficiency can influence intracellular cholesterol content/distribution and lysosomal efficacy, triggering the accumulation of toxic APP-cleaved products, eventually leading to cell death.

  17. Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease.

  18. This study provides a novel mechanism underlying aggregation of Abeta peptides via BC1 induction of APP mRNA translation.

  19. This study uncovered two clear phases in the life of APP23 mice: developmental and aging. Development displays similarities to young carriers of familial Alzheimer's disease (AD) mutations. All gene expression differences between APP23 and control mice correlate with aging. Age-related expression changes appear exacerbated/accelerated in APP23 mice.

  20. These results provide evidence for an emerging role of BAG-1M in the regulation of BACE1 expression and AD pathogenesis and that targeting the BAG-1M-NF-kappaB complex may provide a mechanism for inhibiting Abeta production and plaque formation.

beta Amyloid (Abeta) profil antigène

Antigen Summary

This gene encodes a cell surface receptor and transmembrane precursor protein that is cleaved by secretases to form a number of peptides. Some of these peptides are secreted and can bind to the acetyltransferase complex APBB1/TIP60 to promote transcriptional activation, while others form the protein basis of the amyloid plaques found in the brains of patients with Alzheimer disease. Mutations in this gene have been implicated in autosomal dominant Alzheimer disease and cerebroarterial amyloidosis (cerebral amyloid angiopathy). Multiple transcript variants encoding several different isoforms have been found for this gene.

Gene names and symbols associated with Amyloid beta (Abeta) Kits ELISA

  • amyloid beta precursor protein (APP) anticorps
  • amyloid beta precursor protein (app) anticorps
  • amyloid beta precursor protein (App) anticorps
  • amyloid beta (A4) precursor protein (App) anticorps
  • aaa anticorps
  • Abeta anticorps
  • Abpp anticorps
  • ad1 anticorps
  • Adap anticorps
  • Ag anticorps
  • appi anticorps
  • betaApp anticorps
  • ctfgamma anticorps
  • Cvap anticorps
  • E030013M08Rik anticorps
  • PN-II anticorps
  • pn2 anticorps

Protein level used designations for Amyloid beta (Abeta) Kits ELISA

alzheimer disease amyloid protein , amyloid beta A4 protein , beta-amyloid peptide , cerebral vascular amyloid peptide , peptidase nexin-II , preA4 , protease nexin-II , amyloid beta (A4) precursor protein (peptidase nexin-2, Alzheimer disease) , amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) , beta-amyloid precursor protein , alzheimer disease amyloid A4 protein homolog , amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease) , ABPP , AG , amyloid A4 , amyloidogenic glycoprotein , appican , protease nexin II

GENE ID SPECIES
351 Homo sapiens
448208 Xenopus (Silurana) tropicalis
100427716 Macaca mulatta
54226 Rattus norvegicus
11820 Mus musculus
Fournisseurs de qualité sélectionnés pour beta Amyloid (Abeta) Kits ELISA
Avez-vous cherché autre chose?